The present work aimed to evaluate, through ten different studies, the therapeutic efficacy of a new pour-on formulation, containing 1.5 per cent ivermectin +0.5 per cent abamectin, against parasites of cattle. Results obtained on trials against Rhipicephalus (Boophilus) microplus showed that the pour-on combination of 1.5 per cent ivermectin +0.5 per cent abamectin obtained superior efficacy indexes against this ectoparasite, when compared with formulations containing 0.5 per cent ivermectin, 1 per cent ivermectin and the combination of 1 per cent abamectin +20 per cent levamisole. The results of efficacy of the ivermectin+abamectin and the 0.5 per cent ivermectin against Haematobia irritans were similar. Against Cochliomyia hominivorax larvae, all pour-on formulations tested (1.5 per cent ivermectin +0.5 per cent abamectin, 0.5 per cent ivermectin and 0.5 per cent abamectin), as well as 1 per cent doramectin administered subcutaneously, were considered ineffective. Cattle medicated with 1.5 per cent ivermectin +0.5 per cent abamectin, pour-on, remained free from parasitism by Dermatobia hominis larvae during 42 days (96 per cent efficacy), while values superior to 90 per cent were obtained by 0.5 per cent ivermectin (92 per cent) and 0.5 per cent abamectin (93 per cent) until the 42nd and 35th days post treatment, respectively. Against Haemonchus placei and Oesophagostomum radiatum, the pour-on of ivermectin+abamectin showed better efficacy than the 0.5 per cent ivermectin and 0.5 per cent abamectin. As to Cooperia punctata, there was no difference regarding efficacy results obtained by the avermectins combination and abamectin. The pour-on combination of 1.5 per cent ivermectin +0.5 per cent abamectin obtained high efficacy against R. (B.) microplus, D. hominis and some species of cattle gastrointestinal helminths when compared with formulations of 0.5 per cent ivermectin and 0.5 per cent abamectin administered through the same route.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4567150 | PMC |
| http://dx.doi.org/10.1136/vetreco-2014-000072 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A 5-year single-center review of seropositivity in kidney transplant candidates in Central Texas.
Proc (Bayl Univ Med Cent)
September 2024
Division of Infectious Disease, University of Michigan, Ann Arbor, Michigan, USA.
Introduction: is a soil-transmitted helminth that can lead to life-threatening hyperinfection in transplant recipients. Targeted screening based on social history alone may preclude a large proportion of seropositive patients. Our institution implemented universal screening for kidney transplant candidates.
View Article and Find Full Text PDFDeath from COVID-19 of a 57-year-old man refusing medical care and self-medicating with ivermectin.
Cent Eur J Public Health
December 2022
Department of Infectious Diseases and Travel Medicine, Faculty of Medicine in Pilsen, Charles University, Faculty Hospital Pilsen, Pilsen, Czech Republic.
Since December 2019, the new SARS-CoV-2 coronavirus causes COVID-19 disease worldwide, which occurs mainly in unvaccinated elderly and polymorbid patients with a more severe course and increased risk of complications and death. Vaccination and specific therapy for the disease using mainly new antiviral drugs are the way to reduce the number of infected, hospitalized patients with a more severe course. We present a case report of an at-risk polymorbid 57-year-old man who refused vaccination and standard treatment for COVID-19 disease based on misinformation from the community.
View Article and Find Full Text PDFand cytomegalovirus coinfection in a patient with a transplanted kidney.
Proc (Bayl Univ Med Cent)
November 2021
Department of Internal Medicine, Baylor University Medical Center, Dallas, Texas.
Cytomegalovirus is a major opportunistic infection after transplantation with significant morbidity and mortality for solid organ transplant recipients. Unrecognized infection with may result in significant morbidity and mortality in immunocompromised patients. Coinfection with multiple pathogens is possible, leading to diagnostic delays, and may make treatment more challenging.
View Article and Find Full Text PDFEvidence-based approach to early outpatient treatment of SARS-CoV-2 (COVID-19) infection.
Proc (Bayl Univ Med Cent)
June 2021
Center for Medical Humanities & Ethics, UT Health San Antonio, San Antonio, Texas.
Misinformation and promotion of well-intended but disproved therapies for COVID-19 have plagued evidence-based shared decision-making throughout the COVID-19 pandemic. In times of crisis, clinicians may feel that their strong inclination to prescribe potentially harmful, unproven therapies on behalf of their patients is supported by beneficence. Clinicians should mindfully identify and avoid commission bias during this pandemic, especially as more data have accumulated to assist with clinically sound decision-making.
View Article and Find Full Text PDFGenotypic and allelic frequencies of gene in dogs in Italy.
Vet Rec Open
June 2020
Department of Agricultural and Environmental Sciences-Production, Landscape, Agroenergy, Università degli Studi di Milano, Milano, Lombardia, Italy.
Background: A mutation in the canine multidrug resistance gene (also referred as ), encoding for the multidrug resistance () P-glycoprotein (P-gp) transponder, causes a pathological condition known as 'ivermectin toxicosis'. The causative mutation, known since 2001, has been described to affects sheep herding breeds related to collie lineage. The present study is a retrospective investigation of the presence of mutated allele in Italian dog populations in a 5 years' time lapse.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!